Table 1_Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflamm

A 2026 retrospective cohort study of 60 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) compares the efficacy of three treatments: ripertamab, rituximab, and efgartigimod. The study, authored by Yutong Wu and shared on figshare, analyzes treatment response, relapse rates, safety, and biomarker correlations. It reports changes in the INCAT score at a 3-month post-treatment assessment.

Use Cases

• Compare short-term treatment efficacy based on reported changes in the INCAT score.
• Analyze relapse rates and drug safety profiles for three different CIDP treatments.
• Explore correlations between biomarker characteristics and disease activity mentioned in the study.
• Benchmark real-world clinical outcomes for ripertamab against established treatments like rituximab.

Strengths

• Study includes 60 patient records from a multicenter cohort.
• Reports specific quantitative outcomes, such as mean INCAT score changes at 3 months for each treatment group.
• Data is shared under a permissive CC-BY-4.0 license.

Limitations

• The dataset is very small at 37.1 KB, indicating limited scope.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale analysis.

Provenance

Source

figshare

Collection Method

Multicenter, retrospective cohort study.

Freshness

Last updated 2026-05-19 05:29:25; freshness should be verified.